Apparently, experience doesn't count for everything: Aside from Gillis' problems with Bexxar, Henney is steering his current company, Dendreon (nasdaq: DNDN - news - people ), out of some recent disappointments over a prostate cancer vaccine.
FORBES: Feeling Corixa's Pain